Skip to content

US · IQV · MEDICAL - DIAGNOSTICS & RESEARCH

IQVIA Holdings Inc. (IQV) intrinsic value and stock valuation

$245.82as of 2026-11-21 · Mkt cap 38.85B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

IQVIA Holdings Inc. DCF and intrinsic value

InvestorsCraft values IQV with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from IQV’s statements →

IQVIA Holdings Inc. Graham Number

Graham Number: $82.86d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Durham, NC 27703 iqvia.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$16.3B+7.5% 5y CAGRd
20112025
Net income
$1.36B+37.3% 5y CAGRd
20112025
Free cash flow
$2.05B+8.8% 5y CAGRd
20112025
Total equity
$6.63B+1.1% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$16.3B$15.4B$15B$14.4B$13.9B
Operating income$2.29B$2.2B$1.98B$1.8B$1.39B
Net income$1.36B$1.37B$1.36B$1.09B$966M
EPSd$7.84M$7.49M$7.29M$5.72M$4.95M
Operating cash flow$2.65B$2.72B$2.15B$2.26B$2.94B
Capital expenditure-$-603M-$-602M-$-649M-$-674M-$-640M
Free cash flow$2.05B$2.11B$1.5B$1.59B$2.3B
Total assets$29.9B$26.9B$26.7B$25.3B$24.7B
Total debt$16.2B$14.2B$13.9B$13B$12.4B
Net debt$14.2B$12.5B$12.5B$11.8B$11.1B
Total equity$6.63B$6.07B$6.11B$5.77B$6.04B
Cash and short-term investments$2.14B$1.84B$1.5B$1.31B$1.48B
Income statement
20252024202320222021
Revenue$16.3B$15.4B$15B$14.4B$13.9B
Cost of revenue$12B$10B$9.75B$9.38B$9.23B
Gross profit$4.29B$5.38B$5.24B$5.03B$4.64B
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$2B$1.99B$2.05B$2.07B$1.96B
Other expenses$0.00$1.18B$1.21B$1.16B$1.28B
Operating expenses$2B$3.17B$3.26B$3.23B$3.25B
Cost and expenses$14B$13.2B$13B$12.6B$12.5B
Interest income$45M$47M$36M$13M$6M
Interest expense$729M$670M$672M$416M$375M
Depreciation and amortization$1.14B$1.11B$1.13B$1.13B$1.26B
Ebitda$3.46B$3.45B$3.26B$2.91B$2.77B
Operating income$2.29B$2.2B$1.98B$1.8B$1.39B
Total other income/expenses, net-$-674M-$-533M-$-518M-$-448M-$-259M
Income before tax$1.61B$1.67B$1.46B$1.35B$1.13B
Income tax expense$252M$296M$101M$260M$163M
Net income$1.36B$1.37B$1.36B$1.09B$966M
Weighted average shares outstanding$171.9M$181.3M$183.8M$187.6M$191.4M
Weighted average diluted shares outstanding$173.5M$183.4M$186.3M$190.6M$195M
Balance sheet
20252024202320222021
Cash and short-term investments$2.14B$1.84B$1.5B$1.31B$1.48B
Net receivables$3.43B$3.24B$3.41B$2.96B$2.61B
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$6.25B$5.83B$5.6B$4.98B$4.76B
Property, plant and equipment, net$823M$773M$819M$863M$903M
Goodwill and intangible assets$21.6B$19.2B$19.4B$18.7B$18.2B
Long-term investments$432M$374M$239M$162M$164M
Total non-current assets$23.7B$21.1B$21.1B$20.4B$19.9B
Total assets$29.9B$26.9B$26.7B$25.3B$24.7B
Accounts payable$3.75B$736M$709M$645M$621M
Short-term debt$1.84B$1.15B$718M$152M$91M
Deferred revenue$2.12B$1.78B$1.8B$1.8B$1.83B
Total current liabilities$8.34B$6.96B$6.49B$5.58B$5.24B
Long-term debt$14.3B$13B$13.2B$12.9B$12.3B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$15B$13.9B$14.1B$14B$13.4B
Capital lease obligations$225M$173M$223M$264M$313M
Total liabilities$23.3B$20.8B$20.6B$19.6B$18.6B
Common stock$11.4B$3M$3M$10.9B$3M
Retained earnings$7.43B$6.07B$4.69B$3.33B$2.24B
Accumulated other comprehensive income (loss)-$-943M-$-1.04B-$-867M-$-727M-$-406M
Total equity$6.63B$6.07B$6.11B$5.77B$6.04B
Total investments$593M$515M$359M$255M$275M
Total debt$16.2B$14.2B$13.9B$13B$12.4B
Net debt$14.2B$12.5B$12.5B$11.8B$11.1B
Cash flow statement
20252024202320222021
Net income$1.36B$1.37B$1.36B$1.09B$966M
Depreciation and amortization$1.14B$1.11B$1.13B$1.13B$1.26B
Stock-based compensation$247M$206M$217M$194M$170M
Change in working capital$125M$158M-$-280M-$-84M$680M
Accounts receivable$60M$182M-$-388M-$-421M-$-138M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-96M$115M$267M$427M$244M
Net cash provided by operating activities$2.65B$2.72B$2.15B$2.26B$2.94B
Investments in property, plant and equipment-$-603M-$-602M-$-649M-$-674M-$-640M
Acquisitions, net-$-1.76B-$-710M-$-876M-$-1.34B-$-1.46B
Net cash used for investing activities-$-2.31B-$-1.44B-$-1.6B-$-2.01B-$-2.1B
Common stock issued-$-67M$0.00$0.00$0.00$0.00
Common stock repurchased-$-1.24B-$-1.35B-$-992M-$-1.17B-$-406M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-150M-$-878M-$-382M-$-329M-$-1.24B
Net change in cash$278M$326M$160M-$-150M-$-448M
Cash at end of period$1.98B$1.7B$1.38B$1.22B$1.37B
Operating cash flow$2.65B$2.72B$2.15B$2.26B$2.94B
Capital expenditure-$-603M-$-602M-$-649M-$-674M-$-640M
Free cash flow$2.05B$2.11B$1.5B$1.59B$2.3B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About IQVIA Holdings Inc.

        IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.

        CEO
        Ari Bousbib
        Employees
        93K
        Beta
        1.20

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of IQVIA Holdings Inc. (IQV)?

        IQVIA Holdings Inc. (IQV) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is IQV undervalued?

        IQV trades at a price of $245.82 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.